Dr Lal PathLabs Share Price in Focus; To Acquire 70% Stake in SN Genelab for Up to ₹168 Crore

Dr Lal PathLabs has approved the purchase of a 70% stake in SN Genelab Private Limited (SN Gene) from its existing shareholders, as per an exchange filing dated September 24, 2026.  

SN Gene will become a subsidiary of Dr Lal PathLabs after the transaction.  

Total Deal Value 

The acquisition will be made through cash consideration. Dr Lal PathLabs will pay up to ₹168 crore for the 70% stake, according to the company’s disclosure. The deal also includes a performance-linked earn-out capped at ₹31.5 crore.  

The transaction does not fall under related party transactions, the company said. No government or regulatory approval has been specified as being required for completing the acquisition.  

SN Gene’s Financials 

SN Gene operates in diagnostics, with a focus on genomics services. The company reported turnover of ₹57.96 crore in FY2026, compared with ₹53.36 crore in FY2025 and ₹43.27 crore in FY2024.  

The company was incorporated on December 16, 2013, in Gujarat. Its business is centred on providing diagnostics-genomics services.  

Dr Lal PathLabs Genomics Business 

Dr Lal PathLabs has stated that the acquisition is intended to add to its expertise in genomics and expand its portfolio of advanced diagnostic services. The transaction will give it a controlling interest in SN Gene, while the disclosure does not specify any purchase of the remaining 30% stake.  

Completion Timeline 

The transaction is expected to be completed by November 30, 2026. The acquisition involves SN Gene’s existing shareholders and will be funded through cash rather than a share swap.  

The deal puts a value of up to ₹168 crore on the 70% stake, excluding the separate performance-linked earn-out of up to ₹31.5 crore. SN Gene reported ₹57.96 crore in turnover in FY2026. 

Read More: Varun Beverages Share Price in Focus; Enters Exclusive Distribution Agreement with Mondelez South Africa Proprietary! 

Dr Lal PathLabs Share Price Performance  

As of September 25, 2026, 11:30 am, Dr Lal PathLabs share price was trading at ₹1,929.10, a 1.64% decrease from the previous closing price. 

Conclusion  

The acquisition will give Dr Lal PathLabs a 70% stake in SN Genelab, which operates in diagnostics-genomics.The deal includes a performance-linked earn-out capped at ₹31.5 crore. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.